MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Employees of the Month: Amparo Tellez and Marcus Prince
The Sanaria employees of the month for March 2024 are Amparo Tellez and Marcus Prince. Amparo and Marus are members of the Manufacturing team and were nominated for employees of the month for their professionalism, consistency, and flexibility – which is key to prepare and maintain a clean and aseptic manufacturing environment that allows Sanaria operations to meet all regulatory standards.
Sanaria Wins Best Logistics Technology and Cold Chain Delivery Award
On April 2nd, 2024, Sanaria Inc. won the Best Logistics Technology and Cold Chain Delivery Award at the Vaccine Industry Excellence (ViE) Awards at the World Vaccine Congress in Washington, D.C.
Novel vaccine, PfSPZ-LARC2 Vaccine, to prevent malaria infection developed by Seattle Children’s Research Institute and Sanaria ready for human testing
In a report published on March 21, 2024 in EMBO Molecular Medicine (A replication competent Plasmodium falciparum parasite completely attenuated by dual gene deletion) investigators at Seattle Children’s Research Institute and Sanaria Inc. describe the development of a whole malaria parasite vaccine strain that infects the liver, develops to the late liver stage, and then gets completely stuck and cannot burst out of the liver to cause symptomatic blood infection.
Sanaria®/Seattle Children’s PfSPZ-LARC2 Vaccine: finalist in Vaccine Industry Excellence (VIE) awards for Best Prophylactic Vaccine Award
Sanaria®/Seattle Children's PfSPZ-LARC2 Vaccine: finalist in Vaccine Industry Excellence (VIE) awards for Best Prophylactic Vaccine Award!
Sanaria is a finalist in Vaccine Industry Excellence (VIE) awards for Best Logistics Technology & Cold Chain Delivery Award
Sanaria is a finalist in Vaccine Industry Excellence (VIE) awards for Best Logistics Technology & Cold Chain Delivery Award!
Sanaria Inc. Receives Major Funding for Malaria (PfSPZ) Repository
Sanaria receives $1.5M from the Gates Foundation to make PfSPZ Challenge more accessible for future controlled human malaria infections (CHMIs) in the form of a repository.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.